Ocugen (NASDAQ:OCGN) versus Korro Bio (NASDAQ:KRRO) Head-To-Head Contrast

Korro Bio (NASDAQ:KRRO) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Volatility & Risk

Korro Bio has a beta of 3.13, suggesting that its share price is 213% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500.

Insider and Institutional Ownership

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Korro Bio and Ocugen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Korro Bio	N/A	-114.26%	-68.57%
Ocugen	N/A	-127,987.80%	-115.95%

Earnings & Valuation

This table compares Korro Bio and Ocugen”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$2.38 million	61.64	-$117.26 million	($10.00)	-1.00
Ocugen	$4.58 million	76.99	-$67.85 million	($0.26)	-4.00

Ocugen has higher revenue and earnings than Korro Bio. Ocugen is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Korro Bio and Ocugen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1	2	6	3	2.92
Ocugen	1	0	4	0	2.60

Korro Bio currently has a consensus price target of $16.71, suggesting a potential upside of 67.65%. Ocugen has a consensus price target of $9.50, suggesting a potential upside of 813.46%. Given Ocugen’s higher probable upside, analysts clearly believe Ocugen is more favorable than Korro Bio.

Summary

Korro Bio beats Ocugen on 9 of the 14 factors compared between the two stocks.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.